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ABSTRACT 
Matrix tablet is an important tool for controlled and sustained release dosage forms. The oral route remains the most common route for the 
administration of drugs. Tablets offer the lowest cost approach to sustained and controlled release dosage forms. The hydrophilic polymer matrix is 
widely used in this dosage form. The use of different polymers in controlling the release of drugs has become the most important tool in the 
formulation of matrix tablets. The drug releases by both dissolution-controlled as well as diffusion-controlled mechanisms from the matrix. The 
development of oral controlled release systems has been a challenge to formulation scientists due to their inability to restrain and localize the 
system at targeted areas of the gastrointestinal tract. There are several advantages of matrix devices including improved patient compliance due to 
less frequent drug administration, reduction of fluctuation in steady-state drug levels, maximum utilization of the drug, increased safety margin of a 
potent drug. This review aims on the discussion of different materials used to prepare matrix tablets, different types of matrix tablets and the drug 
release mechanism from the matrices. 
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Historically, the oral route is considered as a most popular route in 
the administration of the drug. This is because of the fact the 
gastrointestinal physiology offers more flexibility in designing 
dosage form than any other route. Approximately 50% of the drug 
products available in the market are administered orally. Tablets are 
the most commonly and widely used dosage form. This type of drug 
delivery system is called conventional drug delivery system and is 
known to provide an immediate release of the drug. Such immediate 
release products result in relatively rapid drug absorption and the 
onset of accompanying pharmacodynamics effects [1-3]. 
Developing safe and efficient drug delivery system is one of the 
major challenges in the pharmaceutical industry. Therefore, the 
characteristics of drugs as well as the form in which they are 
delivered must be optimized. Among the oral products, matrix 
tablets are an important tool for the controlled and extended release 
of drug. The oral sustained release system is the most popular, 
desirable and preferred method of administrating therapeutic 
agents for systemic effects in order to increase patient compliance 
and the therapeutic efficacy. The tablet matrix is formed by using 
both hydrophilic polymers and hydrophobic lipids to prolong and 
sustain the rate of drug release. Currently, much attention is being 
paid on the development of matrix sustained formulations such as 
matrix tablets containing hydrogels [4].  
The matrix system containing hydrophobic lipid also has been 
widely used in controlled drug delivery applications due to their 
chemical inertness, cost-effectiveness, regulatory acceptance and 
flexibility of achieving the desired drug release profile [5, 6].  
Because of increased complications and expense involved in the 
marketing of new drug entities, greater attention has focused on the 
development of modified release drug delivery system. A controlled 
release matrix system delivers the drug locally or systemically at a 
predetermined rate for a specified period of time [7, 8]. The goal of 
such systems is to provide desirable delivery profiles that can 
achieve therapeutic plasma levels [9]. Drug release is dependent on 
polymer properties, thus the application of these properties can 
produce well characterized and reproducible dosage forms. 
Sustained release systems include any drug delivery system that 
achieves slow release of drug over an extended period of time. If the 
system is successful in maintaining constant drug levels in the blood 
or target tissue, it is considered as a controlled-release system. 
Controlled release systems can be influenced by physiological 
conditions such as motility, ions, pH and enzymes. Hydrophilic 
matrix systems are among the most commonly used means for oral 
controlled drug delivery as they can reproduce a desirable drug 
profile and are cost effective. The primary mechanism of drug 
release from hydrophilic matrices occurs when the polymer swells 
on contact with the aqueous medium to form a gel layer on the 
surface of the system. The drug then releases by dissolution, 
diffusion and/or erosion [10-12]. 
Vast data were collected over the period of last 20 y to review the 
progressive developments in the field of matrix tablet research. 
Advantages of oral matrix systems  
This type of drug delivery has many benefits over conventional 
dosage forms, some of which are as follows [13-14]: 
1. Easy to manufacture. 
2. The frequency of application of dose is reduced, since the drug is 
released over a longer period of time. This is important to the 
patients with chronic illnesses and need a plasma drug 
concentrations o within its therapeutic range, such as, overnight 
management of pain in terminally ill patients.  
3. ‘Dose dumping’ and toxic effects due to high plasma 
concentration are reduced. 
4. Improvement in patient compliance.  
5. Better control of therapeutic drug concentration. 
6. Improvement in bioavailability of some drugs. 
7. Increase the stability by protecting the drug from hydrolysis or 
other derivative changes in the gastrointestinal tract. 
8. Cost-effective manufacturing is possible, since the number of 
doses are decreased. 
Disadvantages of oral controlled release formulations  
Like other formulations, it also possesses several disadvantages. 
These include [15-16]: 
1. Expensive equipment and inert ingredients are required for 
some formulations.  
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2. The drug release rate can be altered by food and gastric transit time; 
as a result, differences may arise in the release rate between doses.  
3. If the formulations are crushed or chewed, it can lose the ‘slow 
release’ characteristics and possess toxicity.  
4. A direct correlation of in vitro data with in vivo release is not 
possible without thorough and careful analysis. For example, there is 
a difference in the availability of water in different parts of the 
gastrointestinal tract and such factors need to be considered when 
designing tablets for extended release.  
5. The dissolution characteristics should allow for the drug to be 
released in a controlled manner, highlighting the importance for the 
correct selection of polymers according to their physical, mechanical 
and pharmacokinetic properties.  
Rationale of developing sustained release matrix devices 
1. To extend the duration of action of the drug.  
2. To reduce the frequency of dosing.  
3. To reduce inter and intrasubject variability. 
4. To minimize the fluctuations in plasma level.  
5. To improve drug utilization.  
6. To reduce adverse effects. 
Polymers used in matrix tablets 
There are number of polymers which may be used to formulate 
matrix tablets depending on the physicochemical properties of the 
drug substance to be incorporated into matrix system and drug 
release profile required. Polymers used for matrix tablets may be 
classified as [17]:  
1) Hydrogels:  
(a) Poly-hydroxyethyl methacrylate (PHEMA).  
(b) Cross-linked polyvinyl alcohol (PVA). 
(c) Cross-linked polyvinylpyrrolidone (PVP).  
(d) Polyethylene oxide (PEO).  
(e) Polyacrylamide (PA).  
2) Soluble polymers:  
(a) Polyethylene glycol (PEG).  
(b) Polyvinyl alcohol (PVA).  
(c) Polyvinylpyrrolidone (PVP).  
(d) Hydroxypropyl methylcellulose (HPMC).  
3) Biodegradable polymers:  
(a) Polylactic acid (PLA).  
(b) Polyglycolic acid (PGA).  
(c) Polycaprolactone (PCL).  
(d) Polyanhydrides.  
(e) Polyorthoesters.  
4) Non-biodegradable polymers:  
(a) Polyethylene vinyl acetate (PVA).  
(b) Polydimethylsiloxane (PDS).  
(c) Polyether urethane (PEU).  
(d) Polyvinyl chloride (PVC).  
(e) Cellulose acetate (CA).  
(f) Ethyl cellulose (EC).  
5) Mucoadhesive polymers:  
(a) Polycarbophil. 
(b) Sodium Carboxymethylcellulose.  
(c) Polyacrylic acid.  
(d) Tragacanth.  
(e) Methylcellulose.  
(f) Pectin.  
6) Natural gums:  
(a) Xanthan gum.  
(b) Guar gum.  
(c) Karaya gum.  
(d) Gum Arabic.  
(e) Locust bean gum. 
Types of matrix systems 
The matrix system can be divided into five categories depending on 
the types of retarding agents or polymeric materials [17]. 
(1) Hydrophobic matrix system. 
(2) Hydrophilic matrix system. 
(3) Fat-wax matrix system. 
(4) Biodegradable matrix  
(5) Mineral matrix 
(1) Hydrophobic matrix systems 
As the term suggests, the primary rate-controlling components of the 
hydrophobic matrix are water-insoluble in nature. These ingredients 
include waxes, glycerides, fatty acids, and polymeric materials such as 
ethyl cellulose, Methyl Cellulose and acrylate copolymers. To alter drug 
release, it may be necessary to incorporate soluble ingredients such as 
lactose into the formulation. The presence of an insoluble ingredient in 
the formulations helps to maintain the physical dimension of the 
hydrophobic matrix during drug release. As such, diffusion of the active 
ingredient from the system is the release mechanism, and the 
corresponding release characteristic can be described by Higuchi kinetic 
model. In addition, hydrophobic matrix systems providing 
programmable rates of delivery have become more important. Constant 
rate delivery always has been one of the primary targets of controlled 
release system especially for a drug with narrow therapeutic index. 
(2) Hydrophilic matrix system 
The primary rate-limiting ingredients of the hydrophilic matrix are 
polymers that would swell when in contact with the aqueous 
solution and form a gel layer on the surface of the system. When the 
release medium (i.e. water) is thermodynamically compatible with a 
polymer, the solvent penetrates into the free spaces between 
macromolecular chains. The polymer may undergo a relaxation 
process, due to the stress of the penetrated solvent, so that the 
polymer chains become more flexible and the matrix swells. This 
allows the encapsulated drug to diffuse more rapidly out of the 
matrix. On the other hand, it would take more time for the drug to 
diffuse out of the matrix, since matrix swelling lengthens the 
diffusion path. It has been widely known that swelling and diffusion 
are not the only factors that determine the rate of drug release. For 
dissolvable polymer matrix, polymer dissolution is another 
important mechanism that can modulate the drug delivery rate. 
While either swelling or dissolution can be the predominant factor 
for a specific type of polymers, in most cases drug release kinetics is 
a result of a combination of these two mechanisms. The presence of 
water decreases the glassy-rubbery temperature (for HPMC from 
184 °C to below 37 °C), giving rise to the transformation of glassy 
polymer to rubbery phase (gel layer). The enhanced mobility of the 
polymeric chain favors the transport of dissolved drug. Polymer 
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relaxation phenomena determine the swelling or volume increase of 
the matrix. Depending on the polymer characteristics, the polymer 
amount in the rubbery phase, at the surface of the matrix, could 
reach the disentanglement concentration; the gel layer varies in 
thickness and the matrix dissolves or erodes. The concentration at 
which polymeric chains can be considered disentangled was 
demonstrated to correspond to an abrupt change in the rheological 
properties of the gel. It showed a relationship between the 
rheological behaviour of HPMC gels and their erosion rate, 
confirming that the polymer-polymer and polymer water 
interactions are responsible for the gel network structure and its 
sensitivity to erosion. In turn, they affect drug release rate in the 
case of poorly soluble drugs. The main polymers used in hydrophilic 
matrices are Hydroxyl propyl methyl cellulose (HPMC) and Hydroxyl 
propyl cellulose (HPC), Xanthan gum, Carbopol 940 and Alginates. 
Hydrogel polymers were much investigated in the literature on the 
basis of drug release and release mechanism from hydrophilic 
matrix tablets as well as pellets. Hydroxyl propyl methyl cellulose 
(HPMC) and hydroxyl propyl cellulose (HPC) polymers achieve 
considerable attention due to their unique properties, and they can 
display good compression characteristics, including when directly 
compressed. They are nontoxic and can accommodate the high level 
of drug loading, and also having adequate swelling properties that 
allows rapid formation of an external gel layer, which retards or 
plays a major role in controlling drug release. Furthermore, HPMC 
polymers are well known as pH-independent materials, this 
advantage enables them to the drug is entrapped in the glassy-
rubbery core in the dry state. It forms a gelatinous layer upon 
hydration. However, this gelatinous layer is significantly different 
structurally from the traditional matrix tablets. 
 
 
Fig. 1: Possible drug release mechanism from various matrix systems [18] 
 
(3) Fat-wax matrix systems 
The drug can be incorporated into fat-wax granulations by spray 
congealing in the air, blend congealing in an aqueous media with or 
without the aid of a surfactant and spray-drying techniques. In the 
bulk congealing method, a suspension of drug and melted fat-wax is 
allowed to solidify and is then comminuted for sustained release 
granulations. The mixture of active ingredients, waxy materials and 
fillers also can be converted into granules by compacting with roller 
compactor, heating in a suitable mixture such as fluidized-bed and a 
steam jacketed blender or granulating with a solution of waxy 
Material or other binders. The drug embedded into a melt of fats and 
waxes is released by leaching and/or hydrolysis as well as the 
dissolution of fats under the influence of enzymes and pH change in 
the gastrointestinal tract. The addition of surfactants to the 
formulation can also influence both the drug release rate and the 
proportion of total drug that can being corporate into a matrix [19]. 
(4) Biodegradable matrix systems 
Biodegradable matrices are composed of monomers linked to one 
another through functional groups with unstable linkage. They degraded 
by enzymes generated by surrounding living cells or by nonenzymatic 
process into oligomers and monomers in the biological systems. Therese 
oligomers and monomers are then metabolized or excreted.  
Examples are natural polymers such as proteins and poly-
saccharides; modified natural polymers; synthetic polymers such as 
aliphatic poly (esters) and poly anhydrides [20].  
(5) Mineral matrices 
The polymers obtained from different species of seaweeds are used to 
prepare mineral matrices. Alginic acid, a hydrophilic carbohydrate 
obtained from brown seaweeds (Phaephyceae) by the use of dilute 
alkali. On the basis of porosity of matrixthese are classified as (a) Macro 
porous; (b) Microporous and (c) Non-porous systems. 
In macro porous systems, the diffusion of drug occurs through pores 
of the matrix, which are of size range 0.1 to 1 μm. In microporous 
system, the diffusion occurs essentially through pores but the pore 
size ranges between 50–200 Å. In non-porous system no pores are 
found and the molecules diffuse through the network meshes [21]. 
Different factors effecting rate drug release from matrix 
systems 
The release of drug from polymer matrix system is dependent upon 
the physicochemical properties of both drug and polymer as well as 
it is also dependent on several biological parameters [21].  
Physicochemical factors 
(1) Swelling property of polymer: Polymer dissolution includes 
absorption/adsorption of water in more accessible places, rupture of 
polymer-polymer linking with the simultaneous forming of water-
polymer linking, separation of polymeric chains, swelling and finally 
dispersion of polymeric chain in dissolution medium. Therefore, study of 
polymer hydration/swelling process for the polymers is required. 
Mondal 
Int J App Pharm, Vol 10, Issue 1, 2018, 1-6 
 
4 
(2) Drug solubility: Molecular size and water solubility of the drug 
are determinants in the release of drug from swelling and erosion 
controlled polymeric matrices. For drugs with reasonable aqueous 
solubility, the release of drugs occurs by dissolution infiltration 
medium and for drugs with poor solubility release occurs by both 
dissolution of drug and dissolution of drug particles through erosion 
of the matrix tablet. 
(3) Solubility: In view of in vivo sink condition maintained actively 
by hem perfusion, it is logical that all the in vitro drug release studies 
should also be conducted under perfect sink condition.  
(4) Polymer diffusivity: The diffusion of small molecules in polymer 
structure is energy activated process in which the diffusing molecules 
move to a successive series of equilibrium position when a sufficient 
amount of energy of activation for diffusion Ed
(5) Thickness of polymer diffusional path: The controlled release 
of a drug from both capsule and matrix type polymeric drug delivery 
system is essentially governed by Fick’s law of diffusion: J D = D 
dc/dx Where, J D is flux of diffusion across a plane surface of unit 
area D is diffusibility of drug molecule, dc/dx is concentration 
gradient of drug molecule across a diffusion path with thickness dx.  
 has been acquired by 
the diffusing molecules. It is dependent on length of polymer chain 
segment, cross linking and crystalline nature of polymers. The release 
of the drug may be attributed to the three factors such as polymer 
particle size, polymer viscosity and polymer concentration. 
(6) The thickness of hydrodynamic diffusion layer: The 
magnitude of drug release value decreases on increasing the 
thickness of hydrodynamic diffusion layer δ d.  
(7) Drug loading dose: The effect of initial drug loading of the tablets 
on the resulting release kinetics is more complex in case of poorly 
water-soluble drugs, with increasing initial drug loading the relative 
release rate first decreases and then increases, whereas, absolute 
release rate monotonically increases. When the amount of drug 
present at a certain position within the matrix, exceeds the amount of 
drug soluble under given conditions, the excess of the drug has to be 
considered as non-dissolved and thus not available for diffusion.  
(8) Diluent’s effect: The Water soluble diluents like lactose cause 
marked an increase in drug release rate and release mechanism is 
also shifted towards Fickian diffusion; while insoluble diluents like 
dicalcium phosphate reduce the Fickian diffusion and increase the 
relaxation (erosion) rate of the matrix. The reason behind this is that 
water-soluble filler in matrices stimulates the water penetration into 
inner part of matrix, due to increase in hydrophilicity of the system, 
causing rapid diffusion of the drug, leads to increased drug release 
rate.  
(9) Additives: The effect of adding non-polymeric excipients to a 
polymeric matrix has been claimed to produce an increase in the 
release rate of hydrosoluble active principles.  
(10) Dose size: For orally administered systems, there is an upper 
limit to the bulk size of the dose to be administered. Compounds that 
require large dosing size can sometimes be given in multiple 
amounts or formulated into liquid systems. Another consideration is 
the margin of safety involved in the administration of a large amount 
of a drug with a narrow therapeutic range.  
(11) Ionization, pka and aqueous solubility: Most drugs are weak 
acids or bases. Since the unchanged form of a drug preferentially 
permeates across lipid membranes, it is important to note the 
relationship between the pka of the compound and the absorptive 
environment. Delivery systems that are dependent on diffusion or 
dissolution will likewise be dependent on the solubility of the drug in 
aqueous media. These dosage forms must function in an environment 
of changing pH, the stomach being acidic and the small intestine more 
neutral, the effect of Phone the release process must be defined. 
Compounds with very low solubility (<0.01 mg/ml) are inherently 
sustained, since their release over the time course of a dosage form in 
the GI tract will be limited by dissolution of the drug.  
(12) Partition coefficient: It is common to consider that the 
biological membranes are lipidic; therefore the partition coefficient 
of oil-soluble drugs becomes important in determining the 
effectiveness of membrane barrier penetration. Compounds which 
are lipophilic in nature having high partition coefficient are poorly 
aqueous. Sustained release drug delivery system is not required to 
retain in the lipophilic tissue for the longer time. In case of 
compounds with low partition coefficient, it is difficult for them to 
penetrate the membrane, resulting in poor bioavailability. The 
choice of diffusion-limiting membranes must largely depend on the 
partitioning characteristics of the drug.  
(13) Stability: Orally administered drugs can be subject to both 
acid-base hydrolysis and enzymatic degradation. For the dosage form 
that are unstable in the stomach, systems that prolong delivery over 
the entire course of transit in the GI tract are beneficial; this is also 
true for systems that delay the release until the dosage form reaches 
the small intestine. Compounds that are unstable in the small intestine 
may demonstrate decreased bioavailability when administered from a 
sustaining dosage form. This is because more drugs is delivered in the 
small intestine and, hence, is subject to degradation. Propantheline 
and probanthine are representative examples of such drug.  
Biological factors 
(1) Biological half-life: Every drug has its own characteristic 
elimination rate, which is the sum of all elimination processes, including 
metabolism, urinary excretion and all over processes that permanently 
remove the drug from the bloodstream. Therapeutic compounds with a 
short half-life are generally are an excellent candidate for sustained 
release formulation, as this reduces dosing frequency. Normally, drugs 
with a half-life shorter than 2 h such as furosemide or levodopa are poor 
candidates for this type of preparation.  
(2) Absorption: If the transit time of any drug in the absorptive 
areas of the GI tract is about 8-12 h, the maximum half-life for 
absorption should be approximately 3-4 h; otherwise, the device will 
pass out of the potential absorptive regions before drug release is 
complete. One method to provide sustaining mechanisms of delivery 
for compounds tries to maintain them within the stomach. This 
allows slow release of the drug, which then travels to the absorptive 
site. Other attempt is to formulate low-density pellet or capsule. 
Another approach is that of bioadhesive materials. 
(3) Metabolism: Drugs those are significantly metabolized before 
absorption, either in the lumen or the tissue of the intestine, can show 
decreased bioavailability from the slower-releasing dosage form.  
Drug release kinetics from sustained release matrix system  
Zero-order kinetics 






 = Amount of drug release dissolved in time‘t’.  
o
K
 = Initial amount of drug concentration in solution. 
0
When the data are plotted as cumulative percent drug release versus 
time, if the plot is linear then data obeys zero order kinetics with 
slope K
t = Zero order rate constant.  
0
First order kinetics 
. This model represents an ideal release profile to achieve 
the prolonged pharmacological action. 
A first order release would be predicted by the following equation:  
Log Qt = Log Qo-K1t/2.303 … Where, Qt = Amount of drug released 
in time‘t’. Qo = Initial amount of drug concentration in solution. K1
Higuchi’s model 
t= 
First order rate constant. When data were plotted as log cumulative 
percent drug remaining verses time yields a straight line indicating 
that the release follows first order kinetics. The constant release 
rate, K can be obtained multiplying slope values. 
Drug release from the matrix device by diffusion has been described 
by Higuchi’s equation:  
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Q = √Dδ/τ (2C-δCs)Cst … Where, Q = Amount of drug released in time‘t’, 
D = Diffusion coefficient of the drug in the matrix. Cs = Solubility of the 
drug in the matrix. δ= Porosity of matrix. τ= Tortuosity. t =Time (h). 
The equation may be simplified then the equation becomes; Q = KH 
×t1/2 Where, KH
When data are plotted according to this equation, i.e., cumulative 
drug released verses square root of time, yields a straight line, 
indicating that the drug was released by diffusion controlled 
mechanism [22]. 
 = Higuchi dissolution constant.  
Drugs suitable to be formulated as matrix tablets 
Drugs with a low half-life (<5 h.), freely soluble in water and larger 
therapeutic window can be formulated as sustained release matrix 
systems. The drugs with suitable polymer and combination of 
polymers to prepare matrix are enlisted in table 1. 
  
Table 1: Combination of few drugs and polymers formulated into matrix tablets 
Drug Polymers Drug Polymers 
Zidovudine HPMC-K4M, Carbopol-934, EC Furosemide Guar gum, Pectin, Xanthan gum 
Venlafexine Beeswax, Caranuaba wax Acarbose HPMC, Eudragit 
Domperidone HPMC-K4M, Carbopol-934 Aceclofenac HPMC-K4M,K15M, K100M,E15,EC, Guar gum 
Alfuzosin HPMC-K15M, Eudragit-RSPO Ambroxol HCL HPMC-K100M, 
Minocycline HPMC-K4M, HPMC-K15M, EC Aspirin EC, Eudragit-RS100, S100 
Ibuprofen EC, CAP Diclofenac Na Chitoson, EC, HPMCP, HPMC 
Metformin HCL HPMC-K100M, EC Diethylcarbamazine citrate Guar gum, HPMC-E15LV 
Propranolol HCL Locust bean gum, HPMC Diltiazem HPMC-K100M, HPMC-K4M, Karaya gum, Locust 
bean gum, Sod. CMC 
Enalpril meleate HPMC-K100M,HPMC K4M, Miconazole Pectin, HPMC 
Flutamide HPMC-K4M, Sod. CMC, Guar gum, 
Xanthan gum 
Naproxen HPMC-K100M, HPMC-K15M, PVP 
Indomethacin EC, HPMC Nicorandil HPMC, CMC, EC 
Chlorpheniramine 
meleate 
Xanthan gum, Chitoson Ondansertan HPMC-K100M, HPMC-K4M, HPMC-K15M 
Itopride HCL HPMC-K100M, HPMC-K4M, EC Phenytoin Na Tragacanth, Acacia, Guar gum, Xanthan gum 
Losartan potassium HPMC-K100M, HPMC-K4M, 
Eudragit-RSPO 
Ranitidine HCL Chitoson, Carbopol-940 
Metoclopromide HPMC, CMC, EC, SSG Theophylline Carbopol-934P, HPMC-K100M, HPMC-K4M, HPMC-
K15M, EC 
Tramadol HPMC-K4M, Karaya gum,  Amlodipine HPMC, EC 
 
CONCLUSION 
From the discussion, it can be concluded that matrix tablets, developed 
by using a rational combination of polymers can successfully applied to 
sustain the release of the drug. Sustaining the release of the drug may be 
helpful in increasing the efficiency of the drug as well as they are also 
useful to improve patient’s compliance. The systems are economic since 
these are developed by using the commonly available polymers. These 
systems are especially useful in case of the patients who need a constant 
delivery of drug for a longer period of time.  
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